AGTX
Agentix Corp., a clinical development stage company, focuses on the development and commercialization of therapeutics to treat metabolic diseases. Its product pipeline includes AGTX-2004, a peripherally-acting CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus; and AGTX-2003, a peripherally-acting CB1 receptor inverse agonist, which has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver diseases. The company was formerly known as FairWind Energy, Inc. and changed its name to Agentix Corp. in June 2019. Agentix Corp. was incorporated in 2013 and is based in Dana Point, California.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q3 | -0.00 | $0 | — |
| 2025 Q2 | -0.00 | $0 | $3,004 |
| 2025 Q1 | -0.00 | $0 | -$118,371 |
| 2025 Q4 | -0.00 | $0 | -$43,060 |
| 2024 Q3 | -0.00 | $0 | -$86,999 |
| 2023 Q1 | -0.01 | $0 | -$62,761 |
| 2023 Q4 | -0.01 | $0 | -$41,300 |
| 2022 Q3 | -0.01 | $0 | $202 |